Table 4.

Comparison of EQ-5D and SF-6D in patient subgroups where there were expected improvements in health status

Patient subgroup	EQ-5D change from baseline	SF-6D change from baseline
Patients who completed the trial and had no adverse events	0.252	0.094
Patients who completed the trial and had >30% pain relief	0.286	0.113
Patients with at least one AE	0.157	0.049
Patients with an AE that lead to withdrawal	0.073	0.005
Patients who discontinued therapy due to lack of efficacy	0.032	0.006